Carlyle and Arcmont, in collaboration with Natixis, have arranged a €470 million financing package to support Bianalisi's growth and consolidation within the Italian healthcare diagnostics market.

Information on the Target

Bianalisi is a premier independent platform for integrated healthcare diagnostics in Italy, distinguished by its extensive services in clinical laboratory diagnostics, outpatient care, and diagnostic imaging. The company operates a robust network that includes 350 laboratories and sample collection points, over 70 outpatient care facilities, and 46 diagnostic imaging centers spread across 13 Italian regions. Throughout its 30-year history, Bianalisi has experienced notable growth, both organically and through strategic mergers and acquisitions, largely due to the efforts of its skilled management team, which is currently led by CEO Giovanni Gianolli. Following an investment from Charme Capital Partners, a prominent Italian private equity firm, in 2021, Bianalisi's expansion has accelerated, enabling the completion of over 60 acquisitions since that time.

Industry Overview in Italy

The Italian healthcare diagnostics sector is characterized by a growing demand for integrated and efficient diagnostic services, driven by an aging population and a rising prevalence of chronic diseases. The market is quite fragmented, with numerous small and medium-sized players, which presents a significant opportunity for consolidation. Moreover, advancements in technology and diagnostics are driving innovations in outpatient services and laboratory testing, contributing to improved patient outcomes and greater efficiency within the healthcare system.

A focus on preventive healthcare is also gaining momentum, further emphasizing the need for comprehensive diagnostic solutions. As healthcare organizations seek to enhance their service delivery, investments in diagnostic i